Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Coenzyme I for Injection on Vascular Aging.
Sponsor: Shanghai 10th People's Hospital
Summary
Emerging evidence identifies vascular aging independently predicting cardiovascular events, yet effective clinical interventions remain lacking. Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor whose levels decline with age, and preclinical studies suggest that boosting NAD+ can improve vascular function and structure. Preliminary clinical studies in healthy older adults indicate that supplementation with NAD+ precursors, such as nicotinamide riboside(NR) or nicotinamide mononucleotide (NMN), can reduce arterial stiffness as measured by pulse wave velocity (PWV). However, whether NAD+ supplementation can improve vascular endothelial function and exert anti-stiffening effects in patients who have already developed measurable arterial stiffness remains unknown. Based on this evidence, the investigator hypothesize that the Coenzyme I for Injection will reverse vascular aging in older adults with established arterial stiffening.
Official title: A Randomized, Double-blind, Parallel Controlled Clinical Trial to Evaluate the Efficacy of Coenzyme I for Injection in the Treatment of Vascular Aging(Pilot Stydy)
Key Details
Gender
All
Age Range
40 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-01-16
Completion Date
2027-12-31
Last Updated
2026-01-08
Healthy Volunteers
No
Conditions
Interventions
Coenzyme I for Injection
Subjects receive 7 consecutive days of intravenous infusion of Coenzyme I for injection.
NaCl (placebo)
Subjects receive 7 consecutive days of intravenous infusion of NaCl(0.9%).
Locations (1)
Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, China